Cencora, Inc. (NYSE:COR) CEO Sells $2,553,859.92 in Stock

Cencora, Inc. (NYSE:COR) CEO Steven H. Collis sold 10,754 shares of the stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $237.48, for a total value of $2,553,859.92. Following the transaction, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at approximately $67,702,698.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Cencora Trading Up 0.8 %

COR opened at $239.13 on Friday. Cencora, Inc. has a 52 week low of $163.37 and a 52 week high of $246.75. The business has a fifty day simple moving average of $237.67 and a 200-day simple moving average of $215.04. The firm has a market cap of $47.70 billion, a P/E ratio of 26.05, a P/E/G ratio of 1.82 and a beta of 0.45. The company has a quick ratio of 0.52, a current ratio of 0.88 and a debt-to-equity ratio of 3.94.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, January 31st. The company reported $3.28 EPS for the quarter, topping the consensus estimate of $2.86 by $0.42. Cencora had a return on equity of 323.23% and a net margin of 0.69%. The business had revenue of $72.25 billion during the quarter, compared to analyst estimates of $68.81 billion. During the same period last year, the business posted $2.71 earnings per share. On average, equities analysts expect that Cencora, Inc. will post 13.43 earnings per share for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 26th. Stockholders of record on Friday, February 9th were paid a $0.51 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.24. This represents a $2.04 annualized dividend and a dividend yield of 0.85%. The ex-dividend date of this dividend was Thursday, February 8th. Cencora’s dividend payout ratio (DPR) is presently 22.22%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on COR. Mizuho upped their price target on Cencora from $192.00 to $224.00 and gave the company a “neutral” rating in a research report on Monday, February 5th. Leerink Partnrs reiterated an “outperform” rating on shares of Cencora in a research report on Monday, February 26th. StockNews.com upgraded Cencora from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 1st. SVB Leerink assumed coverage on Cencora in a research report on Monday, February 26th. They issued an “outperform” rating and a $261.00 price objective for the company. Finally, Barclays assumed coverage on Cencora in a research report on Wednesday, January 3rd. They issued an “overweight” rating and a $242.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $218.22.

Institutional Trading of Cencora

Several hedge funds have recently modified their holdings of COR. Rise Advisors LLC acquired a new stake in shares of Cencora in the first quarter valued at $25,000. Harbour Investments Inc. raised its stake in shares of Cencora by 61.8% in the first quarter. Harbour Investments Inc. now owns 165 shares of the company’s stock valued at $26,000 after acquiring an additional 63 shares in the last quarter. CVA Family Office LLC acquired a new stake in shares of Cencora in the first quarter valued at $34,000. MBM Wealth Consultants LLC acquired a new stake in shares of Cencora in the fourth quarter valued at $41,000. Finally, KB Financial Partners LLC acquired a new stake in shares of Cencora in the first quarter valued at $42,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.